Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 15/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481735 | 0.81 | IMPDH2 (0.53) | IMPDH2AAK1MEN1KMT2AROCK2 | |
| SCHEMBL6493900 | 0.77 | IMPDH2 (0.47) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL16388849 | 0.76 | IMPDH2 (0.53) | IMPDH2AAK1ROCK2ROCK1IMPDH1 | |
| SCHEMBL16388848 | 0.74 | IMPDH2 (0.52) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL16388850 | 0.72 | IMPDH2 (0.49) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL1474411 | 0.71 | IMPDH2 (1.00) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL14518615 | 0.70 | IMPDH2 (0.74) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL15741660 | 0.69 | IMPDH2 (0.76) | IMPDH2AAK1ROCK2ROCK1IMPDH1 | |
| SCHEMBL6483095 | 0.69 | IMPDH2 (0.52) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL3995894 | 0.68 | IMPDH2 (0.82) | IMPDH2AAK1IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1276739-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2001081340-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | IMPDH2 3/4885AAK1 4153/4885MEN1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.